Press release
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2025-2034), Examine DelveInsight | Roche, Elevar Therapeutic, BMS, Merck, Daiichi Sankyo, Genentech, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison
HER2+ Gastric Cancer Market Insights
DelveInsight's latest report, "HER2+ Gastric Cancer - Market Insight, Epidemiology And Market Forecast - 2034", provides an in-depth analysis of the evolving treatment landscape, epidemiological trends, and market dynamics across the 7MM. The report highlights advancements in HER2-targeted therapies, immunotherapy combinations, and antibody-drug conjugates (ADCs) that are poised to transform patient outcomes in this aggressive cancer subtype.
Download the report to understand which factors are driving the HER2 Positive Gastric Cancer therapeutic market @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates. The US also accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.
As per DelveInsight's estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034. This growth is driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options. Several pipeline drugs for HER2+ gastric cancer, including Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN 002 (Enliven Therapeutics), ARX788 (Ambrx), and Rilvegostomig (AstraZeneca), are in development.
Discover evolving trends in HER2+ Gastric Cancer patient pool forecasts @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Additionally, recent therapy approvals such as ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen) are further fueling the market growth. The FDA has also approved HLX02 (Henlius Biotech), a HERCEPTIN biosimilar, as an adjuvant therapy for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Despite the active landscape of HER2+ gastric cancer therapeutics, there is a continued need for the development of novel drugs that are more effective and less toxic. DelveInsight's leading oncology consultant notes, "One of the major challenges in treating HER2-positive gastric cancer is the development of resistance to existing therapies. It is indicated that up to 70% of patients who progress after the initial trastuzumab treatment may lose HER2 expression or acquire genetic alterations that render them resistant to further anti-HER2 therapies." This underscores the potential impact of emerging therapies in revolutionizing HER2-positive gastric cancer treatment.
Unlock which emerging HER2+ gastric cancer drug is expected to capture the largest market share in 7MM by 2034. Visit https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Recent developments, such as the US FDA's Breakthrough Therapy designation given to Zanidatamab in November 2024 and significant clinical trial updates for Evorpacept, highlight the momentum in the field.
In summary, the factors mentioned above are contributing to the significant expansion of the HER2+ gastric cancer market, suggesting a future where improved screening, innovative drug delivery systems, and novel therapies will transform the management of a disease that continues to challenge clinicians and patients alike.
Scope of the HER2+ Gastric Cancer Market Report:
Study Period: 2020-2034
Coverage: 7MM [US, UK, EU4 (France, Germany, Italy, and Spain), and Japan]
Key HER2+ Gastric Cancer Companies
Key HER2+ Gastric Cancer Therapies
HER2+ Gastric Cancer Therapeutic Assessment
HER2+ Gastric Cancer Market Dynamics
Competitive Intelligence Analysis
HER2+ Gastric Cancer Unmet Needs, KOL Views, Analyst Views, HER2+ Gastric Cancer Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. HER2+ Gastric Cancer Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. HER2+ Gastric Cancer Background and Overview
8. HER2+ Gastric Cancer Treatment
9. HER2+ Gastric Cancer Epidemiology and Patient Population in the 7MM
10. HER2+ Gastric Cancer Patient Journey
11. HER2+ Gastric Cancer Marketed Drug
12. HER2+ Gastric Cancer Emerging Drugs
13. HER2+ Gastric Cancer: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2025-2034), Examine DelveInsight | Roche, Elevar Therapeutic, BMS, Merck, Daiichi Sankyo, Genentech, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison here
News-ID: 4258490 • Views: …
More Releases from DelveInsight Business
Tongue Cancer Market Insights: Technological Advances, FDA Approvals, and Clinic …
Key tongue cancer companies driving the innovation and addressing the unmet needs in this therapeutic space include Modra Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Cipla Inc., Eli-Lilly, F. Hoffmann-La Roche, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., MERCK & CO. INC., VIATRIS INC., Sanofi S.A, Teva Pharmaceuticals Industries Ltd, GSK, Novartis, Pfizer and Orca Healthcare, among others.
DelveInsight's "Tongue Cancer - Market Insight, Epidemiology and Market Forecast - 2032" report provides a detailed…
Hepatitis A Market Outlook: Strong Pipeline, Strategic Collaborations, and Incre …
The Hepatitis A market is projected to experience robust growth, fueled by the launch of innovative therapies, rising disease prevalence, and heightened healthcare investments across key regions. Industry leaders, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, Sinovac Biotech Co., Ltd, Sanofi, GlaxoSmithKline, Crucell Holland BV, and Merck, among others, are at the forefront of research and development initiatives in this therapeutic area.
DelveInsight's latest report titled "Hepatitis A…
Chronic Spontaneous Urticaria Market Growth: Market Forecast, Emerging Therapies …
DelveInsight's "Chronic Spontaneous Urticaria Market Insight, Epidemiology And Market Forecast-2034" report provides an in-depth understanding of chronic spontaneous urticaria, its historical and forecasted epidemiology, and the chronic spontaneous urticaria market trends in the 7MM, which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
According to the report, the chronic spontaneous urticaria treatment landscape is poised for significant transformation as the market size, valued at…
Ocular Melanoma Market Analysis: Rising Prevalence, Breakthrough Therapies & Mar …
The 7MM ocular melanoma market is expected to grow substantially in the next 10 years, fueled by advancements in diagnostics and therapeutics, an increasing disease prevalence, and rising healthcare investments globally. Leading Ocular Melanoma companies involving - Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others are actively involved in research…
More Releases for HER2
Evolving Market Trends In The HER2-Negative Breast Cancer Industry: Regulatory A …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected HER2-Negative Breast Cancer Market Size During the Forecast Period?
The market size of HER2-negative breast cancer has witnessed robust growth lately. With a projected growth at a compound annual growth rate (CAGR) of 8.1%, the market size will balloon from $16.29 billion in 2024 to reach $17.62 billion…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
